In situ programming of leukaemia-specific t cells using synthetic DNA nanocarriers

Nature Nanotechnology

Volumn 12, Issue 8, 2017, Pages 813-822

  Smith, Tyrel T ^a   Stephan, Sirkka B ^a   Moffett, Howell F ^a   McKnight, Laura E ^a   Ji, Weihang ^a   Reiman, Diana ^a   Bonagofski, Emmy ^a   Wohlfahrt, Martin E ^a   Pillai, Smitha P S ^a   Stephan, Matthias T ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOMOBILE MANUFACTURE; DISEASES; GENES; NANOPARTICLES; PATIENT TREATMENT; T-CELLS; TUMORS;

ANTIGEN RECEPTORS; CANCER PATIENTS; CELL NUCLEUS; GENES ENCODING; NANO-CARRIERS; POLYMER NANOPARTICLES; SYNTHETIC DNA; TUMOUR CELLS;

CYTOLOGY;

ACETIC ACID; CHIMERIC ANTIGEN RECEPTOR; NANOCARRIER; NANOPARTICLE; PLASMID DNA; POLYMER; TRANSPOSASE; DNA; DRUG CARRIER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER REGRESSION; CAR GENE; CELL BASED GENE THERAPY; CELL NUCLEUS; FEMALE; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENE; ANIMAL; CELLULAR IMMUNITY; CHEMISTRY; DRUG EFFECT; GENE TRANSFER; GENETICS; IMMUNOLOGY; LEUKEMIA; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DNA; DRUG CARRIERS; GENE TRANSFER TECHNIQUES; IMMUNITY, CELLULAR; LEUKEMIA; MICE; NANOPARTICLES; RECEPTORS, CHIMERIC ANTIGEN; T-LYMPHOCYTES;

EID: 85017503720     PISSN: 17483387     EISSN: 17483395     Source Type: Journal    
DOI: 10.1038/NNANO.2017.57     Document Type: Article

References (32)

1. Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).
2. Plumridge, H. New costly cancer treatments face hurdles getting to patients. The Wall Street Journal (6 October 2014); https://www.wsj.com/articles/new-costly-cancer-treatments-face-hurdles-getting-to-patients-1412627150
3. Mangraviti, A. et al. Polymeric nanoparticles for nonviral gene therapy extend brain tumor survival in vivo. ACS Nano 9, 1236–1249 (2015).
4. Narayanan, K. et al. Mimicking cellular transport mechanism in stem cells through endosomal escape of new peptide-coated quantum dots. Sci. Rep. 3, 2184 (2013).
5. Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
6. Davila, M. L., Kloss, C. C., Gunset, G. & Sadelain, M. CD19 CAR-targeted T cells induce long-term remission and B cell aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS ONE 8, e61338 (2013).
7. Nakazawa, Y. et al. Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes. J. Immunother. 36, 3–10 (2013).
8. Burnight, E. R. et al. A hyperactive transposase promotes persistent gene transfer of a piggyBac DNA transposon. Mol. Ther. Nucleic Acids 1, e50 (2012).
9. Gade, T. P. et al. Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res. 65, 9080–9088 (2005).
10. Maude, S. L., Teachey, D. T., Porter, D. & Grupp, S. A. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood 125, 4017–4023 (2015).
11. Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509–1518 (2013).
12. Rosenberg, S. A. Cell transfer immunotherapy for metastatic solid cancer—what clinicians need to know. Nat. Rev. Clin. Oncol. 8, 577–585 (2011).
13. Wang, X. et al. Large-scale clinical-grade retroviral vector production in a fixed-bed bioreactor. J. Immunother. 38, 127–135 (2015).
14. Kuchenbaecker, K. B. et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat. Genet. 47, 164–171 (2015).
15. Johnson, L. A. et al. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci. Transl. Med. 7, 275ra222 (2015).
16. Magnani, C. F. et al. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved sleeping beauty transposon platform. Oncotarget 7, 51581–51597 (2016).
17. Abate-Daga, D. et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum. Gene Ther. 25, 1003–1012 (2014).
18. Sadelain, M. CAR therapy: the CD19 paradigm. J. Clin. Invest. 125, 3392–3400 (2015).
19. Meacham, C. E. & Morrison, S. J. Tumour heterogeneity and cancer cell plasticity. Nature 501, 328–337 (2013).
20. Li, X. et al. Nanoparticle-mediated transcriptional modification enhances neuronal differentiation of human neural stem cells following transplantation in rat brain. Biomaterials 84, 157–166 (2016).
21. Kim, J., Kang, Y., Tzeng, S. Y. & Green, J. J. Synthesis and application of poly (ethylene glycol)-co-poly(beta-amino ester) copolymers for small cell lung cancer gene therapy. Acta Biomater. 41, 293–301 (2016).
22. Zhang, X., Edwards, J. P. & Mosser, D. M. The expression of exogenous genes in macrophages: obstacles and opportunities. Methods Mol. Biol. 531, 123–143 (2009).
23. + cells using lentiviral vectors with regulatory sequences from the CD4 gene. Blood 101, 3416–3423 (2003).
24. Ellmeier, W., Sunshine, M. J., Losos, K., Hatam, F. & Littman, D. R. An enhancer that directs lineage-specific expression of CD8 in positively selected thymocytes and mature T cells. Immunity 7, 537–547 (1997).
25. Wu, C. Y., Rupp, L. J., Roybal, K. T. & Lim, W. A. Synthetic biology approaches to engineer T cells. Curr. Opin. Immunol. 35, 123–130 (2015).
26. Kebriaei, P. et al. Phase I trials using sleeping beauty to generate CD19-specific CAR T cells. J. Clin. Invest. 126, 3363–3376 (2016).
27. Monjezi, R. et al. Enhanced CAR T-cell engineering using non-viral sleeping beauty transposition from minicircle vectors. Leukemia 31, 186–194 (2017).
28. Brooks, P. J., Yang, N. N. & Austin, C. P. Gene therapy: the view from NCATS. Hum. Gene Ther. 27, 7–13 (2016).
29. Gaspar, V. et al. Minicircle DNA vectors for gene therapy: advances and applications. Expert Opin. Biol. Ther. 15, 353–379 (2015).
30. Dobrenkov, K. et al. Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. J. Nucl. Med. 49, 1162–1170 (2008).
31. Fischer, K., Andreesen, R. & Mackensen, A. An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity. J. Immunol. Methods 259, 159–169 (2002).
32. May, C. et al. Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin. Nature 406, 82–86 (2000).